Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
226.10
+2.15 (0.96%)
At close: Jan 30, 2026, 4:00 PM EST
226.09
-0.01 (0.00%)
After-hours: Jan 30, 2026, 5:47 PM EST
Ascendis Pharma Employees
Ascendis Pharma had 1,017 employees as of December 31, 2024. The number of employees increased by 138 or 15.70% compared to the previous year.
Employees
1,017
Change (1Y)
138
Growth (1Y)
15.70%
Revenue / Employee
$745,912
Profits / Employee
-$268,740
Market Cap
13.88B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 1,017 | 138 | 15.70% |
| Dec 31, 2023 | 879 | 82 | 10.29% |
| Dec 31, 2022 | 797 | 158 | 24.73% |
| Dec 31, 2021 | 639 | 157 | 32.57% |
| Dec 31, 2020 | 482 | 152 | 46.06% |
| Dec 31, 2019 | 330 | 114 | 52.78% |
| Dec 31, 2018 | 216 | 79 | 57.66% |
| Dec 31, 2017 | 137 | 36 | 35.64% |
| Dec 31, 2016 | 101 | 23 | 29.49% |
| Dec 31, 2015 | 78 | 23 | 41.82% |
| Dec 31, 2014 | 55 | 10 | 22.22% |
| Dec 31, 2013 | 45 | 7 | 18.42% |
| Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Moderna | 5,800 |
| Bio-Techne | 3,100 |
| BioMarin Pharmaceutical | 3,040 |
| Jazz Pharmaceuticals | 2,800 |
| Exelixis | 1,147 |
| Ionis Pharmaceuticals | 1,069 |
| Roivant Sciences | 750 |
| BridgeBio Pharma | 730 |
ASND News
- 18 days ago - Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 21 days ago - Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 22 days ago - Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript - Seeking Alpha
- 22 days ago - Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) - GlobeNewsWire
- 25 days ago - Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Here's My Prediction For Who Could Acquire Ascendis Pharma - Seeking Alpha
- 7 weeks ago - Eight stock picks to play one of the healthiest corners of the market - Market Watch
- 7 weeks ago - High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth - Seeking Alpha